SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-017202
Filing Date
2019-05-08
Accepted
2019-05-08 16:13:35
Documents
61
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aimt-10q_20190331.htm   iXBRL 10-Q 2524062
2 EX-31.1 aimt-ex311_7.htm EX-31.1 19444
3 EX-31.2 aimt-ex312_6.htm EX-31.2 19447
4 EX-32.1 aimt-ex321_8.htm EX-32.1 16879
  Complete submission text file 0001564590-19-017202.txt   8684966

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA aimt-20190331.xsd EX-101.SCH 52779
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE aimt-20190331_cal.xml EX-101.CAL 79969
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aimt-20190331_def.xml EX-101.DEF 150958
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE aimt-20190331_lab.xml EX-101.LAB 465490
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aimt-20190331_pre.xml EX-101.PRE 330311
10 EXTRACTED XBRL INSTANCE DOCUMENT aimt-10q_20190331_htm.xml XML 1674853
Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)

IRS No.: 452748244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37519 | Film No.: 19806752
SIC: 2834 Pharmaceutical Preparations